167 related articles for article (PubMed ID: 22926257)
1. Powerful inhibition of in-vivo growth of experimental hepatic cancers by bombesin/gastrin-releasing peptide antagonist RC-3940-II.
Szepeshazi K; Schally AV; Rick FG; Block NL; Vidaurre I; Halmos G; Szalontay L
Anticancer Drugs; 2012 Oct; 23(9):906-13. PubMed ID: 22926257
[TBL] [Abstract][Full Text] [Related]
2. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
Stangelberger A; Schally AV; Varga JL; Hammann BD; Groot K; Halmos G; Cai RZ; Zarandi M
Prostate; 2005 Aug; 64(3):303-15. PubMed ID: 15754342
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II.
Kahán Z; Sun B; Schally AV; Arencibia JM; Cai RZ; Groot K; Halmos G
Cancer; 2000 Mar; 88(6):1384-92. PubMed ID: 10717621
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of growth of OV-1063 human epithelial ovarian cancers and c- jun and c- fos oncogene expression by bombesin antagonists.
Chatzistamou I; Schally AV; Sun B; Armatis P; Szepeshazi K
Br J Cancer; 2000 Oct; 83(7):906-13. PubMed ID: 10970693
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin analogues and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of human glioblastomas in vitro and in vivo.
Pinski J; Schally AV; Halmos G; Szepeshazi K; Groot K
Cancer Res; 1994 Nov; 54(22):5895-901. PubMed ID: 7954420
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice.
Stangelberger A; Schally AV; Varga JL; Zarandi M; Szepeshazi K; Armatis P; Halmos G
Clin Cancer Res; 2005 Jan; 11(1):49-57. PubMed ID: 15671527
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of growth of human malignant glioblastoma in nude mice by antagonists of bombesin/gastrin-releasing peptide.
Kiaris H; Schally AV; Sun B; Armatis P; Groot K
Oncogene; 1999 Nov; 18(50):7168-73. PubMed ID: 10597318
[TBL] [Abstract][Full Text] [Related]
8. Effective inhibition of experimental human ovarian cancers with a targeted cytotoxic bombesin analogue AN-215.
Engel JB; Keller G; Schally AV; Halmos G; Hammann B; Nagy A
Clin Cancer Res; 2005 Mar; 11(6):2408-15. PubMed ID: 15788692
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effect of bombesin receptor antagonist RC-3095 on the growth of human pancreatic cancer cells in vivo and in vitro.
Qin Y; Ertl T; Cai RZ; Halmos G; Schally AV
Cancer Res; 1994 Feb; 54(4):1035-41. PubMed ID: 8313359
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and luteinizing hormone-releasing hormone antagonist SB-75 on the growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice.
Yano T; Pinski J; Szepeshazi K; Halmos G; Radulovic S; Groot K; Schally AV
Cancer; 1994 Feb; 73(4):1229-38. PubMed ID: 8313327
[TBL] [Abstract][Full Text] [Related]
11. Bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II inhibit tumor growth and decrease the levels and mRNA expression of epidermal growth factor receptors in H-69 small cell lung carcinoma.
Koppán M; Halmos G; Arencibia JM; Lamharzi N; Schally AV
Cancer; 1998 Oct; 83(7):1335-43. PubMed ID: 9762934
[TBL] [Abstract][Full Text] [Related]
12. Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers.
Rick FG; Buchholz S; Schally AV; Szalontay L; Krishan A; Datz C; Stadlmayr A; Aigner E; Perez R; Seitz S; Block NL; Hohla F
Cell Cycle; 2012 Jul; 11(13):2518-25. PubMed ID: 22751419
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and high dose of somatostatin analogue RC-160 on nitrosamine-induced pancreatic cancers in hamsters.
Szepeshazi K; Schally AV; Cai RZ; Radulovic S; Milovanovic S; Szoke B
Cancer Res; 1991 Nov; 51(21):5980-6. PubMed ID: 1682039
[TBL] [Abstract][Full Text] [Related]
14. Growth inhibition of non-small-cell lung carcinoma by BN/GRP antagonist is linked with suppression of K-Ras, COX-2, and pAkt.
Hohla F; Schally AV; Kanashiro CA; Buchholz S; Baker B; Kannadka C; Moder A; Aigner E; Datz C; Halmos G
Proc Natl Acad Sci U S A; 2007 Nov; 104(47):18671-6. PubMed ID: 18003891
[TBL] [Abstract][Full Text] [Related]
15. Alterations of EGFR/HER, angiogenesis and apoptosis pathways after therapy with antagonists of growth hormone releasing hormone and bombesin in non-small cell lung cancer.
Kanashiro CA; Schally AV; Zarandi M; Hammann BD; Varga JL
Int J Oncol; 2007 Apr; 30(4):1019-28. PubMed ID: 17332943
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
Pinski J; Reile H; Halmos G; Groot K; Schally AV
Cancer Res; 1994 Jan; 54(1):169-74. PubMed ID: 7903203
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of growth of ES-2 human ovarian cancers by bombesin antagonist RC-3095, and luteinizing hormone-releasing hormone antagonist Cetrorelix.
Chatzistamou I; Schally AV; Szepeshazi K; Groot K; Hebert F; Arencibia JM
Cancer Lett; 2001 Sep; 171(1):37-45. PubMed ID: 11485826
[TBL] [Abstract][Full Text] [Related]
18. Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin.
Szepeshazi K; Schally AV; Treszl A; Seitz S; Halmos G
Anticancer Drugs; 2008 Apr; 19(4):349-58. PubMed ID: 18454045
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of growth of HT-29 human colon cancer xenografts in nude mice by treatment with bombesin/gastrin releasing peptide antagonist (RC-3095).
Radulovic S; Miller G; Schally AV
Cancer Res; 1991 Nov; 51(21):6006-9. PubMed ID: 1682040
[TBL] [Abstract][Full Text] [Related]
20. Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice.
Jungwirth A; Galvan G; Pinski J; Halmos G; Szepeshazi K; Cai RZ; Groot K; Schally AV
Prostate; 1997 Aug; 32(3):164-72. PubMed ID: 9254895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
